Skip to main content
Erschienen in: World Journal of Urology 3/2008

01.06.2008 | Topic Paper

The face of high risk prostate cancer

verfasst von: Peter C. Albertsen

Erschienen in: World Journal of Urology | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To define high risk prostate cancer using prostate cancer specific mortality as the key outcome metric.

Methods

Data from two population based cohorts of men from Connecticut who were diagnosed with localized prostate cancer were analyzed to determine the natural history of prostate cancer and the impact of treatment on long term survival.

Results

Men with Gleason 7–10 prostate cancer and a potential survival of 10 years have a high risk of dying from their disease if they elect active surveillance. Surgery appears to offer an improved survival for these men when compared to radiation therapy or observation. Men diagnosed with Gleason 6 tumors in the contemporary era are more likely to harbor low risk prostate cancer when compared to historical series.

Conclusions

Our studies confirm that high risk prostate cancer is best identified by Gleason score 7–10, but challenge the concept that men with high-grade disease are less likely to benefit from radical surgery. Men who have rising PSA values following treatment with either surgery or radiation have residual prostate cancer and are at very high risk of dying from prostate cancer within 10 years.
Literatur
1.
Zurück zum Zitat D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH (2003) Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21:2163–2172PubMedCrossRef D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH (2003) Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21:2163–2172PubMedCrossRef
2.
Zurück zum Zitat Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55–74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975–980PubMedCrossRef Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55–74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975–980PubMedCrossRef
3.
Zurück zum Zitat Albertsen PC, Hanley JA, Fine J (2005) 20–year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101PubMedCrossRef Albertsen PC, Hanley JA, Fine J (2005) 20–year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101PubMedCrossRef
4.
Zurück zum Zitat Albertsen PC, Hanley JA, Penson DF, Barrows F, Fine J (2007) Thirteen-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 177:932–936PubMedCrossRef Albertsen PC, Hanley JA, Penson DF, Barrows F, Fine J (2007) Thirteen-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 177:932–936PubMedCrossRef
5.
Zurück zum Zitat Epstein JI (2000) Gleason 2–4 adenocarcinoma of the prostate on needle biopsy. Am J Surg Pathol 24:477–478PubMedCrossRef Epstein JI (2000) Gleason 2–4 adenocarcinoma of the prostate on needle biopsy. Am J Surg Pathol 24:477–478PubMedCrossRef
6.
Zurück zum Zitat Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PDH, Sanders MM, Fine J (2005) Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97:1248–1253PubMedCrossRef Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PDH, Sanders MM, Fine J (2005) Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97:1248–1253PubMedCrossRef
7.
Zurück zum Zitat Albertsen PC, Hanley JA, Penson DF, Fine J (2004) Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 171:2221–2225PubMedCrossRef Albertsen PC, Hanley JA, Penson DF, Fine J (2004) Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 171:2221–2225PubMedCrossRef
8.
Zurück zum Zitat Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO (2004) Natural history of early, localized prostate cancer. JAMA 291:2713–2719PubMedCrossRef Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO (2004) Natural history of early, localized prostate cancer. JAMA 291:2713–2719PubMedCrossRef
9.
Zurück zum Zitat Bill-Axelson A, Holmberg L, Ruutu M et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977–1984PubMedCrossRef Bill-Axelson A, Holmberg L, Ruutu M et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977–1984PubMedCrossRef
10.
Zurück zum Zitat Chism DB, Hanlon AL, Tronsco P, Al-Saleem T, Horowitz EM, Pollack A (2003) The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys 56:1241–1247PubMedCrossRef Chism DB, Hanlon AL, Tronsco P, Al-Saleem T, Horowitz EM, Pollack A (2003) The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys 56:1241–1247PubMedCrossRef
11.
Zurück zum Zitat Smith EB, Frierson HF, Mills SE et al. (2002) Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years. Cancer 94:2282–2287PubMedCrossRef Smith EB, Frierson HF, Mills SE et al. (2002) Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years. Cancer 94:2282–2287PubMedCrossRef
12.
Zurück zum Zitat Schellhammer P, Moriarty R, Bostwick D et al. (2000) Fifteen year minimum follow-up of a prostate brachytherapy series: comparing the past with the present. Urology 56:436–439PubMedCrossRef Schellhammer P, Moriarty R, Bostwick D et al. (2000) Fifteen year minimum follow-up of a prostate brachytherapy series: comparing the past with the present. Urology 56:436–439PubMedCrossRef
13.
Zurück zum Zitat Pound DR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597PubMedCrossRef Pound DR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597PubMedCrossRef
Metadaten
Titel
The face of high risk prostate cancer
verfasst von
Peter C. Albertsen
Publikationsdatum
01.06.2008
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 3/2008
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-008-0254-3

Weitere Artikel der Ausgabe 3/2008

World Journal of Urology 3/2008 Zur Ausgabe

Männern mit Zystitis Schmalband-Antibiotika verordnen

03.05.2024 Zystitis Nachrichten

Die akute Zystitis von Männern und ihre Therapie sind wenig erforscht. Norwegische Forscher haben das nachgeholt. Ihr Rat: Erst einmal keine Breitbandantibiotika verordnen.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

D-Mannose ohne Nutzen in der Prävention von HWI-Rezidiven

D-Mannose, eine Hoffnungsträgerin in der Rezidivprophylaxe von Harnwegsinfektionen, hat in einer Studie nicht mehr bewirken können als ein Placebo. Die Empfehlung zur Einnahme entfalle damit, so die Autoren.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.